Centogene N.V. (Nasdaq: CNTG), a commercial-stage Company focused
on generating data-driven insights to diagnose, understand, and
treat rare diseases, and Twist Bioscience Corporation (Nasdaq:
TWST), a Company enabling customers to succeed through its offering
of high-quality synthetic DNA using its silicon platform, announced
today that they have signed a contract to collaborate on the
development and commercialization of custom assay kits for rare
diseases. The resulting products will be designed to make genetic
testing more accessible to patients and further drive the
understanding of rare diseases. Financial details were not
disclosed.
“We are excited to be working together with Twist as we seek to
enable the most timely diagnosis for rare disease patients around
the world,” said Andrin Oswald, M.D., Chief Executive Officer at
CENTOGENE. “Not only will this help to provide patients with
quicker and more comprehensive answers today, but it will generate
insights to advance the precision medicine of tomorrow.”
The product offering will combine CENTOGENE’s rare disease
diagnostic expertise powered by the world’s largest Bio/Databank of
its kind with Twist Bioscience’s library preparation and target
enrichment capabilities to deliver multiple assays for rare disease
diagnosis and analysis. The aim is to increase genetic testing
options for the one in 15 individuals that are diagnosed with a
rare disease each year. Additionally, the insights generated
through these products will augment the Bio/Databank on rare
diseases and may contribute to the discovery and development of
novel therapeutics to treat rare diseases in the future.
“Twist continues to deliver science-driven tools to enable the
accurate identification of rare diseases,” said Emily M. Leproust,
Ph.D., CEO and Co-Founder of Twist Bioscience. “We look forward to
combining our robust NGS tools with CENTOGENE’s rare disease
insights to truly deliver advanced solutions for research
professionals globally.”
This agreement represents another significant step forward for
CENTOGENE’s mission to drive novel insights and enable the cure of
100 rare diseases within the next 10 years. To learn more, visit:
https://www.centogene.com/virtual-investor-event
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture and academic research.
Follow us
on Twitter | Facebook | LinkedIn | YouTube
About CENTOGENE
CENTOGENE engages in diagnosis and research around rare diseases
transforming real-world clinical, genetic, and multiomic data to
diagnose, understand, and treat rare diseases. Our goal is to bring
rationality to treatment decisions and to accelerate the
development of new orphan drugs by using our extensive rare disease
knowledge and data. CENTOGENE has developed a global proprietary
rare disease platform based on our real-world data repository with
over 3.9 billion weighted data points from approximately 600,000
patients representing over 120 different countries.
The Company’s platform includes epidemiologic, phenotypic, and
genetic data that reflects a global population, as well as a
biobank of patients’ blood samples and cell cultures. CENTOGENE
believes this represents the only platform focused on comprehensive
analysis of multi-level data to improve the understanding of rare
hereditary diseases. It allows for better identification and
stratification of patients and their underlying diseases to enable
and accelerate discovery, development, and access to orphan drugs.
As of December 31, 2020, the Company collaborated with over 30
pharmaceutical partners.
Follow us on LinkedIn | Twitter | Facebook |
Instagram
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the U.S. federal securities laws. Statements
contained herein that are not clearly historical in nature,
including but not limited to statements relating to the
collaboration between CENTOGENE and Twist are forward-looking, and
the words “anticipate,” “believe,” “continues,” “expect,”
“estimate,” “intend,” “project,” and similar expressions and future
or conditional verbs such as “will,” “would,” “should,” “could,”
“might,” “can,” and “may,” are generally intended to identify
forward-looking statements. Such forward-looking statements involve
known and unknown risks, uncertainties, and other important factors
that may cause CENTOGENE’s or Twist’s actual results, performance,
or achievements to be materially different from any future results,
performance, or achievements expressed or implied by the
forward-looking statements. Such risks and uncertainties relating
to CENTOGENE include, among others, negative worldwide economic
conditions and ongoing instability and volatility in the worldwide
financial markets, the effects of the COVID-19 pandemic on its
business and results of operations, possible changes in current and
proposed legislation, regulations and governmental policies,
pressures from increasing competition and consolidation in its
industry, the expense and uncertainty of regulatory approval,
including from the U.S. Food and Drug Administration, its reliance
on third parties and collaboration partners, including its ability
to manage growth and enter into new client relationships, its
dependency on the rare disease industry, its ability to manage
international expansion, its reliance on key personnel, its
reliance on intellectual property protection, fluctuations of its
operating results due to the effect of exchange rates, or other
factors. Such risks and uncertainties relating to Twist include,
among others, the risks and uncertainties of the duration, extent
and impact of the COVID-19 pandemic, including any reductions in
demand for its products (or deferred or canceled orders) globally
or in certain regions; the ability to attract new customers and
retain and grow sales from existing customers; risks and
uncertainties of rapidly changing technologies and extensive
competition in synthetic biology could make the products Twist is
developing obsolete or non-competitive; uncertainties of the
retention of a significant customer; supply chain and other
disruptions caused by the COVID-19 pandemic or otherwise; risks of
third party claims alleging infringement of patents and proprietary
rights or seeking to invalidate Twist’s patents or proprietary
rights; and the risk that Twist’s proprietary rights may be
insufficient to protect its technologies. For further information
on the risks and uncertainties that could cause actual results to
differ from those expressed in these forward-looking statements, as
well as risks relating to CENTOGENE’s business and Twist’s business
in general, see CENTOGENE’s risk factors set forth in CENTOGENE’s
Form 20-F filed on April 15, 2021, with the Securities and Exchange
Commission (the “SEC”) and see Twist’s risk factors set forth in
Twist’s Quarterly Report on Form 10-Q filed with the SEC on August
9, 2021, respectively, and any subsequent filings by CENTOGENE or
Twist with the SEC. Any forward-looking statements contained in
this press release speak only as of the date hereof, each of
CENTOGENE and Twist specifically disclaims any obligation to update
any forward-looking statement, whether as a result of new
information, future events, or otherwise.
Media Contact:
CENTOGENE
Ben Legg
Corporate Communications
Ben.Legg@centogene.com
Lennart Streibel
Investor Relations
Investor.Relations@centogene.com
FTI Consulting
Robert Stanislaro
robert.stanislaro@fticonsulting.com
Rachel Kleiman
rachel.kleiman@fticonsulting.com
Twist Bioscience
Angela Bitting
abitting@twistbioscience.com
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jun 2024 to Jul 2024
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jul 2023 to Jul 2024